Large Chinese Pharma
Pipeline and filing analysis on Hengrui and the other large domestic sponsors.
¥84.2 Million, 84 Centers, $328 Million: Hengrui Took a Drug With No Story All the Way to Filing
HRG2010, Hengrui's carbidopa/levodopa IR/ER capsule for Parkinson's motor fluctuations, never made the company's launch forecast or pipeline appendix — yet quietly finished Phase 3 across 84 centers and filed for approval on August 24, 2026.
September 26, 2026 · 15 min read→Large Chinese Pharma / SHR-1819SHR-1819 Files for Approval: The Sixth Ticket In
Hengrui's anti-IL-4Rα antibody SHR-1819 has just had its marketing application accepted. But five domestic rivals against the same target are already ahead of it.
September 26, 2026 · 20 min read→Large Chinese Pharma / adebrelimabAdebrelimab: a PD-L1 that "doesn't rely on standing out on its own" — how Hengrui uses it to thicken its portfolio
Hengrui's in-house PD-L1 adebrelimab was never going to win on single-agent efficacy — its value is as the “made in-house, paired in-house, sold in-house” immuno-oncology foundation thickening Hengrui's lung-cancer portfolio.
Sep 26, 2026 · 17 min read→Large Chinese Pharma / BHB-1893One Molecule, Two Names, Two Destinies
BHB-1893 and HRS-1893 are the same tablet: on August 6, 2026 its overseas holder used it to open the door to Nasdaq while its Chinese parent had received only US$32.5 million — a case study in timing, structure and irreversibility.
Sep 26, 2026 · 21 min read→Large Chinese Pharma / BHB-1893US$32.5 million in cash, 7.42 million shares What did Hengrui actually keep in BHB-1893?
BHB-1893's Nasdaq listing laid out the full license terms in public filings for the first time, and they differ considerably from the press-release version a year earlier — US$32.5 million in cash, 7.42 million shares, and what Hengrui actually kept.
Sep 26, 2026 · 30 min read→Large Chinese Pharma / DP303cCSPC's DP303c (enweiqutuozhumab): A commercialization test of "beating the comparator, only to face a stronger rival"
With Phase 3 head-to-head data beating T-DM1, an accepted marketing application and a 10,000-strong commercial platform, CSPC's DP303c holds a strong hand — yet faces a battlefield already rewritten by T-DXd.
Sep 26, 2026 · 20 min read→Large Chinese Pharma / HLX04-OHLX04-O: an ophthalmic bevacizumab that was "licensed out", Henlius's light move in the anti-VEGF red ocean
In oncology HLX04-O is Henlius's self-commercialized Hanbeitai, but in ophthalmology its global rights (China included) were licensed out in one go — a clear-eyed calculation on monetizing a non-core asset.
Sep 26, 2026 · 14 min read→Large Chinese Pharma / HRG2010RMB 84.2 million, 84 sites, US$328 million: Hengrui took a drug with no story all the way to a marketing filing
HRG2010 never appeared in Hengrui's innovation narrative — not on its three-year launch forecast, not in its pipeline appendices, not in its J.P. Morgan presentation — yet its marketing application was accepted on August 24, 2026.
Sep 26, 2026 · 24 min read→Large Chinese Pharma / HRS-7535HRS-7535: when an oral weight-loss drug is packed into a “US shell”, what exactly did Hengrui sell?
China's first oral small-molecule GLP-1 to enter Phase 3 trails orforglipron by two years, yet was licensed as part of a bundle to a US NewCo with Hengrui keeping China and taking nearly 20% equity.
Sep 26, 2026 · 19 min read→Large Chinese Pharma / HRS5635HRS-5635: Hengrui bets on the world’s largest hepatitis B market, but both its timing and its posture deserve scrutiny
Hengrui's liver-targeted siRNA HRS-5635 was listed for Breakthrough Therapy Designation in September 2025 for hepatitis B functional cure, but enters a crowded race as a later follower whose value rests on beating the ~20% data yardstick.
Sep 26, 2026 · 17 min read→Large Chinese Pharma / IBI343IBI343: a gastric cancer ADC already “validated globally”, whose real test is its second tumor type
Innovent's anti-CLDN18.2 ADC IBI343 became the first CLDN18.2 ADC accepted for regulatory review in June 2026 and handed ex–Greater China rights to Takeda — but its value ceiling will be decided by pancreatic cancer, not gastric cancer.
Sep 26, 2026 · 16 min read→Large Chinese Pharma / olatorepatideOlatorepatide: how a domestic pharma “built on oncology” turned weight loss into a US$2 billion going-global case study
Olatorepatide delivered 19.3% weight loss with GI tolerability as its differentiator and secured an $80M-upfront / ~$1.93B-milestone ex–Greater China license from Regeneron — “light up front, heavy at the back,” with China as the only anchor Hansoh controls.
Sep 26, 2026 · 14 min read→Large Chinese Pharma / ribupatideRibupatide: a China-originated GLP-1/GIP dual agonist's breakout case study in globalization
Hengrui's GLP-1/GIP dual agonist reaches NDA with 19.2% weight loss and dual injectable/oral formulations, while Kailera tests the NewCo globalization model.
Sep 26, 2026 · 19 min read→Large Chinese Pharma / SHR-1819SHR-1819 files for approval: the sixth entry ticket
Hengrui's anti-IL-4Rα antibody SHR-1819 files for approval as the sixth domestic same-target drug, facing five rivals, a price-set NRDL anchor and a dermatology sales team yet to be built.
Sep 26, 2026 · 21 min read→Large Chinese Pharma / SHR-4640SHR-4640: a "quiet asset" in Hengrui's chronic disease line — can the commercial platform amplify it into the next steady cash card?
SHR-4640, Hengrui's selective URAT1 inhibitor for gout, quietly reaches NDA behind dotinurad — its value lies in Hengrui's chronic-disease commercial platform and regional licensing optionality.
Sep 26, 2026 · 16 min read→Large Chinese Pharma / SHR-A2009SHR-A2009 wins at the PFS interim: in the global HER3 ADC vacuum, Hengrui hands in its answer sheet first
Hengrui's HER3 ADC SHR-A2009 hit statistical significance at its Phase 3 PFS interim one year after HER3-DXd's BLA withdrawal — leaving OS, ILD grading and the ex-China BD decision as the next three tests.
Sep 26, 2026 · 24 min read→Large Chinese Pharma / SSGJ-6113SBio's SSGJ-611: after 707, how to play the IL-4Rα card
3SBio's SSGJ-611, China's third domestic IL-4Rα antibody, must leverage a 2,653-person sales force and the 707 deal's cash to chase Keymed — with regional licensing as the overseas play.
Sep 26, 2026 · 21 min read→Large Chinese Pharma / TQB2102TQB2102: how should a "third-place" asset play its hand?
A HER2 biparatopic ADC whose marketing application was just accepted must play third place behind Enhertu and Hengrui's Aiweida — its real edge is CTTQ's own breast-cancer prescribing network, not its molecule.
Sep 26, 2026 · 30 min read→Large Chinese Pharma / TQB3454TQB3454: on track to be China's first domestic IDH1 inhibitor for IDH1-mutant biliary tract cancer — so why won't it be won or lost in the lab?
With both PFS and OS past superiority boundaries in Phase 3, TQB3454's scientific risk is largely retired — the contest now is commercial execution in a small, biomarker-defined biliary tract cancer market.
Sep 26, 2026 · 20 min read→Large Chinese Pharma / TQB3909TQB3909: when a "technically qualified" BCL-2 inhibitor arrives two or three years late
A technically sound in-house BCL-2 inhibitor that filed with priority review proposed, but as at best the third domestic entrant behind venetoclax, lisaftoclax and sonrotoclax, its value now hinges on in-house combinations rather than monotherapy.
Sep 26, 2026 · 17 min read→Large Chinese Pharma / TQH2722TQH2722 files for approval: 12 days late, and two years late
Twelve days behind Hengrui's SHR-1819 and two years behind stapokibart's launch, TQH2722's real logic is as CTTQ's entry ticket into dermatology — a team “built once, shared” with the oral TYK2 inhibitor TQH3906.
Sep 26, 2026 · 24 min read→Large Chinese Pharma / tecotabart vedotinTecotabart vedotin: Sino Biopharm has bet on a global first — where is the real exam?
The first CLDN18.2 ADC to complete Phase 3 enrollment now sits inside Sino Biopharm — and the next two years (OS readout, 2028 NRDL-aligned NDA, overseas BD window of H2 2026–H1 2027) decide whether “global first” becomes global value.
Sep 26, 2026 · 21 min read→Large Chinese Pharma / UBT251UBT251: selling the world to Novo Nordisk and keeping China for itself — The United Laboratories' "atypical" way of going global
A US$2B “home turf as anchor, world as option” deal — United Laboratories handed ex-Greater China rights to Novo Nordisk while keeping China for its own insulin-built commercial platform.
Sep 26, 2026 · 19 min read→